GlassScriptPhysician profile
David S Kirsch
NPI 1417934035
$1,649.57
in general payments reported to CMS, 2019-2025
13 companies · $269 in 2025
The $269 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $36.54 · 2021: $271 · 2022: $108 · 2023: $422 · 2024: $326 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,018.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $409.35 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Alcon Vision LLC | $274.59 | 2019-2024 | Centurion, Argos, Clareon |
| Astellas Pharma US INC | $250.00 | 2023-2024 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $246.19 | 2019-2021 | |
| Oyster Point Pharma, INC. | $138.12 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $82.95 | 2021-2023 | Xelpros, Cequa |
| Glaukos Corporation | $79.73 | 2019-2023 | Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Tarsus Pharmaceuticals, INC. | $39.01 | 2025 | Xdemvy |
| Trisalus Life Sciences, INC. | $37.26 | 2025 | Trinav Infusion System |
| Amgen INC. | $29.47 | 2025 | Tepezza |
| Dentsply Sirona INC | $24.40 | 2019 | |
| Kala Pharmaceuticals, INC. | $22.67 | 2019 | |
| Allergan, INC. | $15.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kirsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.